Search Results - john+f+hancock

1 Results

Sort By:

Novel Fendiline Derivatives for the Treatment of KRAS Mutant Tumors

RAS is the most common oncogene in human cancer, with ~20% mutation rate in human tumor overall and up to 90% in certain types of cancers (e.g. pancreatic cancer). Responsible for 76% of RAS-mutated cancers of the three RAS genes (HRAS, KRAS, and NRAS), KRAS remains a promising yet challenging therapeutic target despite research efforts for the past...

Published: 1/15/2026 | Inventor(s): John F Hancock

Keywords(s):

Category(s): Oncology, Therapeutics